Tag Archives: Biotech M&A

M&A is an omnipresent reality in the biopharma industry, from Big Pharma mega-mergers to smaller acquisitions of emerging startups. We’ve recently witnessed several large M&A transactions get closed or announced, including BMS-Celgene, Takeda-Shire, and AbbVie-Allergan; according to BMO Capital Markets

Heading into the winter holidays always brings out festive reflections of the past year. Twelve months ago, we were thrilled to say goodbye to 2016 and excited to embrace 2017’s promise.  And in large part, the past year has delivered

Last month, Bloomberg bemoaned the dearth of biotech M&A, and pundits echoed the sentiment (here, here), citing concerns about tax rates and drug pricing. The top line numbers in Bloomberg’s graph certainly paint a dim view of 2017’s global biotech

Lightning can definitely strike the same place twice, or so it seems in biotech. The latest example is True North Therapeutics’ recent acquisition by Bioverativ for its program addressing cold agglutinin disease, a type of rare autoimmune hemolytic anemia: it

As larger Pharma externally-enables more of its pipelines, the cadence of biotech M&A appears to be accelerating, especially for early stage deals. Another week, another biotech acquisition in the news: Allergan has acquired two private and two public R&D-stage companies in just

The maelstrom around drug pricing has continued its fury over the past month, which has led to considerable volatility in the biopharma stock market. Investor fears of draconian price controls that will eliminate the return of investment from innovative pharmaceutical

Similar to this time last year, when IPOs were capturing everyone’s attention, M&A in biotech has been delivering real value.  This morning HBM Partners released their outstanding report on BioPharma M&A in 2014 (here), and the conclusions are in line